VectivBio Holding AG Price & Performance (VECT)

Ironwood Pharmaceuticals has completed its $17-per-share tender offer for VectivBio, securing over 97% of outstanding shares. Following the transaction, Ironwood replaced VectivBio’s board and will proceed with delisting from Nasdaq and a squeeze-out merger under Swiss law, consolidating its rare gastrointestinal disease portfolio.12

Recent corporate actions include multiple biotech firms delisting from major exchanges, with NeuroMetrix, Beacon Roofing Supply, and others pending liquidation. Several companies, such as Petros Pharmaceuticals and Seres Therapeutics, enacted significant reverse stock splits, reflecting ongoing volatility and restructuring within the sector.3

Alentis Therapeutics has closed a $181.4 million Series D financing round, aiming to accelerate clinical development of its anti-Claudin-1 antibody-drug conjugates for solid tumors. The oversubscribed funding underscores investor confidence in Alentis’ innovative approach to cancer and fibrotic disease treatments.4